Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.

You may also be interested in...



Court Upholds Norvasc Patent

Apotex will be prohibited from launching a generic of amlodipine until September 2007, according to a Jan. 18 ruling out of Chicago federal court

Mylan Granted 180-Day Exclusivity On Norvasc

Mylan holds 180-day exclusivity on all three doses of Pfizer's Norvasc following FDA's confirmation that the generic firm was first-to-file on the 2.5 mg, 5 mg and 10 mg amlodipine doses, the company announced Oct. 4

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS064697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel